Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epirubicin + cyclophosphamide + filgrastim + lenograstim
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination chemotherapy regimen consisting of epirubicin (an anthracycline) and cyclophosphamide with granulocyte colony-stimulating factor (G-CSF) support using either filgrastim or lenograstim. The EC component is a standard chemotherapy combination used in breast cancer treatment, while the G-CSF components (filgrastim or lenograstim) are administered to stimulate the production of neutrophils and reduce the risk of febrile neutropenia. This combination is typically administered in cycles every 2-3 weeks.
- Other names
- EC chemotherapy with G-CSF support
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on epirubicin + cyclophosphamide + filgrastim + lenograstim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epirubicin + cyclophosphamide + filgrastim + lenograstim.